0000000000117363

AUTHOR

Charles Coutant

showing 25 related works from this author

Impact of age-related socio-economic and clinical determinants of quality of life among long-term breast cancer survivors.

2015

a b s t r a c t Objectives: The main purpose of this study was to identify age-related socioeconomic and clinical deter- minants of quality of life among breast cancer survivors five years after the diagnosis. The secondary objective was to describe quality of life in the studied population according to age. Study design: A cross-sectional survey in five-year breast cancer survivors was conducted in women diagnosed with breast cancer in 2007 and 2008 in Cote d'Or. Main outcome measures: Quality of life was assessed with the SF-12, the EORTC-QLQ-C30 and the EORTC- QLQ-BR23 questionnaires. Socio-economic deprivation was assessed by the EPICES questionnaire. Social support was assessed by the …

GerontologyAdultCross-sectional studyPopulationBreast NeoplasmsComorbidityGeneral Biochemistry Genetics and Molecular BiologySocial supportBreast cancerQuality of lifeSurveys and QuestionnairesMedicineHumansSurvivorseducationSocioeconomic statusPovertyAgedAged 80 and overeducation.field_of_studybusiness.industryAge FactorsObstetrics and GynecologySocial SupportMiddle Agedmedicine.diseaseComorbidityCross-Sectional StudiesSocioeconomic FactorsQuality of LifeFemaleNeoplasm Recurrence LocalbusinessBody mass indexMaturitas
researchProduct

Incidental findings in a series of 2500 gene panel tests for a genetic predisposition to cancer: Results and impact on patients.

2020

Abstract With next generation sequencing, physicians are faced with more complex and uncertain data, particularly incidental findings (IF). Guidelines for the return of IF have been published by learned societies. However, little is known about how patients are affected by these results in a context of oncogenetic testing. Over 4 years, 2500 patients with an indication for genetic testing underwent a gene cancer panel. If an IF was detected, patients were contacted by a physician/genetic counsellor and invited to take part in a semi-structured interview to assess their understanding of the result, the change in medical care, the psychological impact, and the transmission of results to the f…

0301 basic medicineAdultMalemedicine.medical_specialtyPatientsContext (language use)030105 genetics & heredity03 medical and health sciencesNeoplasmsGeneticsmedicineGenetic predispositionHumansGenetic Predisposition to DiseaseGenetic TestingCHEK2Genetics (clinical)Genetic testingAgedIncidental Findingsmedicine.diagnostic_testbusiness.industryCancerRegretGeneral MedicineMiddle Agedmedicine.disease030104 developmental biologyAttitudeFamily medicineAnxietyFemalemedicine.symptomReturn of resultsbusinessEuropean journal of medical genetics
researchProduct

Impact of sentinel node biopsy on long-term quality of life in breast cancer patients

2013

Background: The aim of this study was to assess long-term quality of life (QoL) over a period of 6 years in women with breast cancer (BC) who underwent sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or SLNB followed by ALND. Methods: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ)-C30 and the EORTC-QLQ-BR-23 questionnaires were used to assess QoL before surgery, just after surgery, 6, 12 and 72 months later. The longitudinal effect of surgical modalities on QoL was assessed with a mixed model analysis of variance for repeated measurements. Results: Five hundred and eighteen BC patients were initially include…

Cancer Researchmedicine.medical_specialtyTime FactorsHealth StatusBreast surgerymedicine.medical_treatmentSentinel lymph nodeBreast Neoplasmsbreast cancerBreast cancerQuality of lifeSurveys and QuestionnairesBody ImageHumansMedicineAgedSentinel Lymph Node Biopsybusiness.industryCarcinoma Ductal BreastAxillary Lymph Node DissectionCancerMiddle AgedSentinel nodemedicine.diseasehumanitiesSurgeryLymphedemaquality of lifeOncologyClinical StudyLymph Node ExcisionFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesBritish Journal of Cancer
researchProduct

Atypical epithelial hyperplasia of the breast: state of the art.

2016

International audience; Introduction: Atypical epithelial hyperplasia (AEH) of the breast is considered benign histological lesions with breast cancer risk. This review focuses on clinical signification and management of AEH that remains controversial. Areas covered: A review of published studies was performed using medline database. In this review, we fully describe the current evidence available. In particular, we describe 1) data from immunohistochemistry and molecular studies that suggest AEH is a precursor of breast cancer; 2) epidemiological studies demonstrate low rate of breast cancer in women with AEH; 3) surgical excision is necessary after diagnosis of AEH, such as lobular carcin…

RiskPathologymedicine.medical_specialtysurgical excisionBiopsyLobular carcinoma[SDV.CAN]Life Sciences [q-bio]/CancerBreast NeoplasmsAtypical ductal hyperplasiacore needle biopsy030218 nuclear medicine & medical imagingatypical lobular hyperplasia03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerBiopsyAtypiaMedicineHumansPharmacology (medical)Epithelial hyperplasiaBreastskin and connective tissue diseaseslobular carcinoma in situHyperplasiamedicine.diagnostic_testbusiness.industryHyperplasiamedicine.diseaseImmunohistochemistry3. Good healthOncologycolumnar cell lesions with atypia030220 oncology & carcinogenesisImmunohistochemistryFemalebusinesslobular neoplasiaPrecancerous ConditionsLobular NeoplasiaExpert review of anticancer therapy
researchProduct

Fertility concerns among young breast cancer survivors in Côte d’Or

2021

Introduction Les effets secondaires des traitements utilises dans la prise en charge du cancer du sein (CS) sur la fonction ovarienne et la fertilite ont largement ete documentes. Cependant, les donnees populationnelles sur les difficultes liees a la fertilite des survivantes jeunes apres un CS sont rares et peu d’etudes ont ete realisees sur cette thematique en France. Cette etude visait a decrire les conditions de vie a long terme, en termes de fertilite, des survivantes jeunes apres un CS en Cote d’Or. Methodes Les femmes âgees de 45 ans et moins au diagnostic d’un CS non metastatique entre 2006 et 2015, ont ete selectionnees a partir du Registre des CS et autres cancers gynecologiques d…

Gynecologymedicine.medical_specialtyEpidemiologyPolitical sciencePublic Health Environmental and Occupational HealthmedicineRevue d'Épidémiologie et de Santé Publique
researchProduct

Prise en charge des proliférations épithéliales du sein avec et sans atypies : hyperplasie canalaire atypique, métaplasie cylindrique avec atypie, né…

2015

In the last few years, diagnostics of high-risk breast lesions (atypical ductal hyperplasia [ADH], flat epithelial atypia [FEA], lobular neoplasia: atypical lobular hyperplasia [ALH], lobular carcinoma in situ [LCIS], radial scar [RS], usual ductal hyperplasia [UDH], adenosis, sclerosing adenosis [SA], papillary breast lesions, mucocele-like lesion [MLL]) have increased with the growing number of breast percutaneous biopsies. The management of these lesions is highly conditioned by the enlarged risk of breast cancer combined with either an increased probability of finding cancer after surgery, either a possible malignant transformation (in situ or invasive cancer), or an increased probabili…

medicine.medical_specialtybusiness.industryRadial scarLobular carcinomaObstetrics and GynecologyCancerGeneral Medicinemedicine.diseaseMalignant transformationBreast cancerReproductive MedicineAtypiaMedicineHistopathologyRadiologyskin and connective tissue diseasesbusinessneoplasmsLobular NeoplasiaJournal de Gynécologie Obstétrique et Biologie de la Reproduction
researchProduct

What Are Young Women Living Conditions after Breast Cancer? Health-Related Quality of Life, Sexual and Fertility Issues, Professional Reinsertion

2020

In recent decades, the living conditions of young breast cancer (BC) survivors have garnered increasing attention. This population-based study aimed to identify the clinical, social and economic determinants of Health-Related Quality of Life (HRQoL), and to describe other living conditions of young long-term BC survivors. Women with non-metastatic BC diagnosed between 2006 and 2015, aged 45 years and younger at the time of diagnosis, were identified through the Breast and Gynecologic Cancer Registry of the C&ocirc

Gerontologymedicine.medical_specialtyCancer ResearchEpidemiologymedia_common.quotation_subjectPopulationPsychological intervention[SDV.CAN]Life Sciences [q-bio]/CancerFertilitylcsh:RC254-282Article03 medical and health sciencesSocial support0302 clinical medicineBreast cancerQuality of lifebreast neoplasmPolitical scienceMedicine030212 general & internal medicineeducationComputingMilieux_MISCELLANEOUSmedia_commonGynecologyHealth related quality of lifefertilityeducation.field_of_studyyoung women[SHS.SOCIO]Humanities and Social Sciences/Sociologybusiness.industryPublic Health Environmental and Occupational Healthreturn to workmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenshumanities3. Good healthsexualityhealth-related quality of lifeSocial deprivationOncology030220 oncology & carcinogenesisAnxiety[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiemedicine.symptombusinessreturn to work.Cancers
researchProduct

Tendances de prescription de l’hormonothérapie et survie chez les femmes atteintes d’un cancer du sein non métastatique à récepteurs hormonaux positi…

2021

Introduction La plupart des donnees sur l’efficacite de l’hormonotherapie proviennent d’essais cliniques randomises. Peu ou moins de donnees existent sur l’efficacite de l’hormonotherapie en vie reelle et sa prescription au cours du temps. Cette etude avait pour objectif d’identifier les facteurs pronostiques de la survie chez les femmes atteintes d’un cancer du sein non metastatique a recepteurs hormonaux positifs (RH +). Methodes Une etude observationnelle retrospective a ete realisee a partir du Registre des cancers du sein et autres cancers gynecologiques de Cote d’Or en France. Toutes les femmes ayant recu un diagnostic de cancer du sein RH + invasif primaire non metastatique entre 199…

EpidemiologyPublic Health Environmental and Occupational HealthRevue d'Épidémiologie et de Santé Publique
researchProduct

Peut-on proposer un prélèvement du ganglion sentinelle en cas de chimiothérapie néoadjuvante dans les cancers du sein et à quel moment ?

2016

The main goal of preoperative chemotherapy is to reduce the size of the tumor and allow conservative treatment. Neoadjuvant treatment can affect axillary status with a downstaging in one third of the cases. For these patients, the benefit of axillary node dissection is questioned and the sentinel node biopsy (SLNB) seems to be a relevant option. However, the timing of performing SLNB is still debated especially for clinical negative patients with negative axillary ultrasound before preoperative chemotherapy. For axillary positive nodes proved by biopsy/cytology before preoperative chemotherapy, SLNB can be an option if there is a good clinical and radiological response.

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrySentinel lymph nodeObstetrics and GynecologyAxillary Node DissectionGeneral Medicine030230 surgerySentinel nodemedicine.disease3. Good health03 medical and health sciences0302 clinical medicineBreast cancerReproductive MedicineNeoadjuvant treatment030220 oncology & carcinogenesisCytologyBiopsyMedicinePreoperative chemotherapyRadiologybusinessGynécologie Obstétrique & Fertilité
researchProduct

Erratum à l’article : « Dépistage du cancer du sein : en route vers le futur » [Bull. Cancer 103 (2016) 753–763]

2016

Gynecology03 medical and health sciencesCancer Researchmedicine.medical_specialtyOncologybusiness.industrymedicineRadiology Nuclear Medicine and imagingHematologyGeneral Medicine030501 epidemiology0305 other medical sciencebusinessBulletin du Cancer
researchProduct

Phase 0/1 of Positron Emission Tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung canc…

2018

e24184Background: Multiple EGFR tyrosine kinase inhibitors (TKIs) are approved for treatment of NSCLC harboring EGFR activating mutations or secondary TKIs resistant mutation. We evaluate a new PET...

Cancer Research[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingnon-small cell lung cancer (NSCLC)[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicinemedicineIn patientComputingMilieux_MISCELLANEOUSmedicine.diagnostic_testbusiness.industryPet imagingmedicine.diseaseEGFR Tyrosine Kinase Inhibitorsrespiratory tract diseases3. Good health[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/ImagingOncologyEgfr mutationPositron emission tomography030220 oncology & carcinogenesisMutation (genetic algorithm)Cancer researchbusiness030215 immunology
researchProduct

Quelle chirurgie après chimiothérapie néoadjuvante ?

2013

La chimiotherapie neoadjuvante (CNA) constitue maintenant une des methodes standards pour traiter les cancers du sein dans le but de permettre, dans certaines conditions, un traitement conservateur pour des tumeurs initialement avancees [1], [2]. Il est necessaire d’optimiser l’approche chirurgicale tant pour le traitement de la tumeur mammaire que pour le geste axillaire.

researchProduct

Stratégies en cas de positivité du ganglion sentinelle dans les cancers du sein

2020

Resume Les strategies de prise en charge en cas de ganglion(s) sentinelle(s) micro ou macrometastatique(s) dans les cancers du sein ont ete profondement modifiees depuis une dizaine d’annees et la publication de cinq essais randomises : ACOSOG Z0011, IBCSG 23-01, et AATRM comparant curage axillaire versus abstention ; et AMAROS et OTOASOR comparant curage axillaire versus radiotherapie axillaire. Malgre les limites methodologiques de certains de ces essais, notamment de l’ACOSOG Z0011, les recommandations internationales (ASCO, NCCN) et le consensus d’experts de St Gallen ne preconisent pas la realisation d’un curage axillaire complementaire en cas d’envahissement macro ou micrometastatique…

0301 basic medicineGynecologyCancer Researchmedicine.medical_specialtybusiness.industryHematologyGeneral Medicine03 medical and health sciences030104 developmental biology0302 clinical medicineAxillary radiotherapyOncology030220 oncology & carcinogenesismedicineRadiology Nuclear Medicine and imagingbusinessBulletin du Cancer
researchProduct

Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by int…

2020

International audience; Introduction The aim of this study was to identify prognostic factors of overall survival in patients with FIGO stage IIIc or IVa ovarian cancer (OC) treated by neo-adjuvant chemotherapy (NAC) followed by interval debulking surgery.Materials and methods Data from 483 patients with ovarian cancer were retrospectively collected, from January 1, 2000 to December 31, 2016, from the FRANCOGYN database, regrouping data from 11 centers specialized in ovarian cancer treatment. Median overall survival was determined using the Kaplan-Meier method. Univariate and multivariate analysis were performed to define prognostic factors of overall survival.Results The median overall sur…

Neoplasm Residualmedicine.medical_treatmentGenes BRCA2FIGO Stage IIICGenes BRCA1Platinum CompoundsCarcinoma Ovarian EpithelialCohort Studies0302 clinical medicineAscitic FluidOverall survivalPeritoneal Lavage030212 general & internal medicineOvarian NeoplasmsUnivariate analysisCytoreduction Surgical ProceduresGeneral MedicineMiddle AgedPrognosisDebulkingNeoadjuvant Therapy3. Good healthSurvival RateOncology030220 oncology & carcinogenesisFemaleTaxoidsFranceOmentumCohort studymedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerAntineoplastic Agents[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetricsInterval debulking surgeryNeoadjuvant chemotherapyPelvis03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerOvarian cancerMedian follow-upmedicineHumansNeoplasm InvasivenessAgedNeoplasm StagingProportional Hazards Modelsbusiness.industryRetrospective cohort studymedicine.diseaseSurgery[SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMultivariate AnalysisLymph Node Excision[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieSurgeryLymphadenectomyLymph NodesOvarian cancerbusinessEuropean Journal of Surgical Oncology
researchProduct

Dépistage du cancer du sein : en route vers le futur

2016

Breast cancer remains a potentially lethal disease, which requires aggressive treatments and is associated with long-term consequences. Its prognosis is linked to both tumor biology and burden at diagnosis. Although treatments have allowed important improvements in prognosis over the past 20 years, breast cancer screening remains necessary. Mammographic screening allows earlier stage diagnoses and a decrease of breast cancer specific mortality. However, breast cancer screening modalities should be revised with the objective to address demonstrated limitations of mammographic screening (limited benefit, imperfect sensitivity and specificity, overdiagnoses, radiation-induced morbidity). Furth…

RiskCancer Researchmedicine.medical_specialtyPersonalized[SDV.CAN]Life Sciences [q-bio]/CancerDiseaseRisque03 medical and health sciencesBreast cancer screening0302 clinical medicineBreast cancerBreast cancer[SDV.CAN] Life Sciences [q-bio]/CancerPersonnalisémedicineMammographyRadiology Nuclear Medicine and imaging030212 general & internal medicineIntensive care medicineScreening proceduresCancer du seinBiomarqueursCancer preventionmedicine.diagnostic_testbusiness.industryHematologyGeneral Medicinemedicine.disease3. Good healthClinical trialOncologyDépistage030220 oncology & carcinogenesisScreeningBiomarker (medicine)businessBiomarkers
researchProduct

Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene

2013

International audience; Fanconi anaemia (FA) is characterized by progressive bone marrow failure, congenital anomalies, and predisposition to malignancy. In a minority of cases, FA results from biallelic FANCD1/BRCA2 mutations that are associated with early-onset leukaemia and solid tumours. Here, we describe the clinical and molecular features of a remarkable family presenting with multiple primary colorectal cancers (CRCs) without detectable mutations in genes involved in the Mendelian predisposition to CRCs. We unexpectedly identified, despite the absence of clinical cardinal features of FA, a biallelic mutation of the FANCD1/BRCA2 corresponding to a frameshift alteration (c.1845_1846del…

AdultBiallelic MutationRNA Splicing[SDV]Life Sciences [q-bio]DNA Mutational AnalysisBiologymedicine.disease_causeArticleFrameshift mutationGeneticsmedicineHumansMissense mutationAge of OnsetGeneAllelesGenetics (clinical)BRCA2 ProteinGeneticsMutationPoint mutationComputational BiologyChromosome BreakageBRCA2 ProteinPedigree3. Good healthAmino Acid SubstitutionMutationFemaleRNA Splice SitesChromosome breakageColorectal NeoplasmsEuropean Journal of Human Genetics
researchProduct

Cancer de l’endomètre. Application des recommandations de 2010 : étude multicentrique

2014

Resume Introduction Le cancer de l’endometre est le plus frequent des cancers gynecologiques. Afin d’ameliorer et d’homogeneiser les prises en charge du cancer de l’endometre, des recommandations ont ete elaborees en novembre 2010. Le but de cette etude est d’evaluer l’application de ces recommandations. Materiel et methode Notre etude multicentrique retrospective utilise les bases de donnees de trois centres francais : le CHU de Reims, l’Hopital Tenon de Paris et le Centre de lutte contre le cancer Georges-Francois-Leclerc de Dijon de novembre 2010 a decembre 2012. Cette etude consistait en l’evaluation des modalites de prise en charge diagnostique et therapeutique des patientes presentant…

GynecologyCancer Researchmedicine.medical_specialtyOncologybusiness.industryMedicineRadiology Nuclear Medicine and imagingHematologyGeneral MedicinebusinessBulletin du Cancer
researchProduct

Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines a…

2021

Summary Purpose In the ACOSOG Z0011 trial, patients with primary breast cancer and 1–2 tumor-involved sentinel lymph nodes (SLNs) undergoing breast-conserving surgery had no oncological outcome benefit after axillary lymph node dissection (ALND), despite a relevant rate of non-SLN metastases of 27%. According to the St Gallen expert consensus, and NCCN and ASCO clinical guidelines, ALND may be avoided in patients who meet all ACOSOG Z0011 inclusion criteria. This recommendation can also be extended to patients undergoing mastectomy, with 1 or 2 positive SLNs and an indication for chest wall radiation, in whom axillary radiotherapy can be proposed as an alternative to completion ALND. The ai…

AdultCancer Researchmedicine.medical_specialtyLymphovascular invasionmedicine.medical_treatmentSentinel lymph nodeBreast NeoplasmsCohort StudiesBreast cancermedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyMastectomySocieties MedicalAgedAged 80 and overbusiness.industryAxillary Lymph Node DissectionCancerHematologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseUnited StatesOncologyLymphatic MetastasisAxillaPractice Guidelines as TopicLymph Node ExcisionFemaleGuideline AdherenceRadiologySentinel Lymph NodebusinessMastectomyBulletin du Cancer
researchProduct

Stadification ganglionnaire lombo-aortique dans les cancers du col de stade supérieur ou égal à IB2: comparaison des performances du PETscan au 18FDG…

2021

Resume Introduction Les recommandations actuelles (ASCO, ESTRO, ESGO) preconisent la realisation d’un curage lombo-aortique (CLAO) de stadification ganglionnaire en cas de negativite au PETscan d’evaluation initiale dans les cancers du col localement avance (CCLA), afin d’adapter les champs d’irradiation de la radiochimiotherapie. L’objectif principal etait de comparer la survie globale (SG) entre deux groupes (iN- au PETscan versus iN- et pN- au PETscan et CLAO) qui different par leur technique de stadification ganglionnaire lombo-aortique: stadification par imagerie seule versus imagerie et chirurgie. Les objectifs secondaires etaient de determiner la survie sans recidive (SSR), le taux d…

Gynecology03 medical and health sciencesmedicine.medical_specialty030219 obstetrics & reproductive medicine0302 clinical medicineReproductive Medicinebusiness.industry030220 oncology & carcinogenesismedicineObstetrics and GynecologyPara aortic lymphadenectomybusinessGynécologie Obstétrique Fertilité & Sénologie 
researchProduct

Seroprevalence of SARs-CoV-2 among the staff and patients of a French cancer centre after first lockdown: the canSEROcov study

2021

Abstract Background In view of the potential gravity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection for patients with cancer, epidemiological data are vital to assess virus circulation among patients and staff of cancer centres. We performed a prospective study to investigate seroprevalence of SARS-CoV-2 antibodies among staff and patients with cancer at a large cancer centre, at the end of the period of first national lockdown in France and to determine factors associated with the risk of SARS-CoV-2 infection. Methods After the first lockdown, all medical and non-medical staff, as well as all patients attending the medical oncology department were invited to unde…

0301 basic medicineMaleCancer ResearchSerology0302 clinical medicineHygieneSeroepidemiologic StudiesEpidemiologyMedicineProspective cohort studyChildmedia_commonOriginal ResearchAged 80 and overserodiagnosisseroprevalenceSocial distanceMiddle AgedSerologyOncology030220 oncology & carcinogenesisChild PreschoolCarrier StateFemaleFrancemedicine.symptomAdultmedicine.medical_specialtyAdolescentmedia_common.quotation_subjectHealth PersonnelSARS-COV-2Cancer Care FacilitiesAsymptomaticCOVID-19 Serological Testingstaff03 medical and health sciencesYoung AdultSeroprevalenceHumansAntibodyAgedbusiness.industryhealthcare workersCancerCOVID-19cancer centerCancer patientsmedicine.diseasePersonnel Hospital030104 developmental biologyFamily medicinebusinessEuropean Journal of Cancer
researchProduct

Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial …

2010

Abstract Purpose: We examined in a prospective, randomized, international clinical trial the performance of a previously defined 30-gene predictor (DLDA-30) of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide (T/FAC) chemotherapy, and assessed if DLDA-30 also predicts increased sensitivity to FAC-only chemotherapy. We compared the pCR rates after T/FAC versus FACx6 preoperative chemotherapy. We also did an exploratory analysis to identify novel candidate genes that differentially predict response in the two treatment arms. Experimental Design: Two hundred and seventy-three patients were randomly assigned to receive eith…

OncologyAdultCancer Researchmedicine.medical_specialtyCyclophosphamidePaclitaxelmedicine.drug_classmedicine.medical_treatmentBreast NeoplasmsAntimetaboliteBiomarkers PharmacologicalArticleBreast cancerPredictive Value of TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansDoxorubicinCyclophosphamideAgedChemotherapybusiness.industryCarcinoma Ductal BreastCancerMiddle Agedmedicine.diseasePrognosisSurgeryGene Expression Regulation NeoplasticTreatment OutcomeOncologyFluorouracilDoxorubicinFemaleBreast diseaseFluorouracilbusinessmedicine.drug
researchProduct

Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

2015

Abstract Purpose: To investigate the value of the metabolic tumor response assessed with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), compared with clinicobiologic markers to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in women with triple-negative breast cancer (TNBC). Experimental Design: Fifty consecutive women with TNBC and an indication for NAC were prospectively included. Different pretreatment clinical, biologic, and pathologic biomarkers, including SBR grade, the Ki-67 proliferation index, androgen receptor expression, EGF receptor (EGFR), and cytokeratin 5/6 staining, were assessed. Tumor glucose metabolism at baseline and its chan…

OncologyAdultCancer Researchmedicine.medical_specialtyPathologyProliferation indexmedicine.medical_treatmentBiopsyTriple Negative Breast NeoplasmsBreast cancerFluorodeoxyglucose F18Internal medicineBiopsyAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansEpidermal growth factor receptorTriple-negative breast cancerNeoadjuvant therapyAgedNeoplasm StagingChemotherapymedicine.diagnostic_testbiologybusiness.industryOdds ratioMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyNeoadjuvant TherapyTumor BurdenGlucoseTreatment OutcomeOncologyROC CurveLymphatic MetastasisPositron-Emission Tomographybiology.proteinFemaleNeoplasm GradingbusinessTomography X-Ray ComputedBiomarkersClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Tumeurs localisées du sein triple négatives en 2016 : définitions et prise en charge

2016

Triple-negative breast cancer (TN), as defined by the triple negativity in immunohistochemistry: the absence of estrogen receptor, progesterone receptor and the absence of overexpression or amplification of HER2, corresponds to 15 % of invasive breast cancers. This is a very heterogeneous group of tumors both at the genomic and transcriptomic level and at morphological, clinical and prognostic level. Although there are some good prognosis forms, the majority of TN tumors is characterized by a poor prognosis with a greater frequency of visceral metastases and a maximum risk of relapse in the first two years after diagnosis. Systemic adjuvant treatment with chemotherapy is almost always indic…

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentObstetrics and GynecologyEstrogen receptorGeneral Medicinemedicine.diseaseSystemic therapyOncologic surgery03 medical and health sciences0302 clinical medicineBreast cancerReproductive Medicine030220 oncology & carcinogenesisInternal medicineProgesterone receptormedicineImmunohistochemistry030212 general & internal medicinebusinessAdjuvantGynécologie Obstétrique & Fertilité
researchProduct

Quel impact de l’ACOSOG sur une cohorte multicentrique française de patientes avec ganglion sentinelle positif ?

2013

L’essai americain ACOSOG Z-0011 a remis en cause l’interet du curage axillaire (CA) en cas d’envahissement limite des ganglions sentinelles (GS) chez les patientes presentant un cancer du sein apres traitement conservateur [1]. En Europe, ce nouveau standard est loin d’etre accepte par tous et de fait, de nombreuses questions demeurent. Quelle proportion de patiente europeenne avec GS+ pourrait beneficier d’une abstention de CA en tenant compte des criteres de l’ACOSOG ? Dans quelle mesure une cohorte selectionnee en Europe selon les criteres ACOSOG differerait de la population rapportee dans l’ACOSOG ? a l’inverse, le pronostic des patientes non eligibles par les criteres de l’ACOSOG est-i…

researchProduct

Long term gynaecological cancer survivors in Cote d'Or: health-related quality of life, social and professional reinsertion

2018

IF 2,392 (2017); International audience

Quality of lifeGynaecological cancer[SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics[SDV.CAN] Life Sciences [q-bio]/CancerProfessional reinsertion[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics
researchProduct